Application of inhibitor of histone methyltransferase EZH2 to preparing medicine for controlling peritoneum fibrosis after peritoneal dialysis

A methyltransferase, peritoneal dialysis technology, applied in the direction of drug combination, medical preparations containing active ingredients, pharmaceutical formulations, etc., can solve the peritoneal function and histopathological changes, limit the application value of CAPD, reduce the ultrafiltration of peritoneal dialysis Volume and other issues, to achieve the effect of reducing peritoneal pathological changes, significant technological progress, and reducing angiogenesis

Inactive Publication Date: 2019-05-10
SHANGHAI EAST HOSPITAL EAST HOSPITAL TONGJI UNIV SCHOOL OF MEDICINE
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, continuous exposure to bioincompatible peritoneal dialysate (PDF) can lead to functional and histopathological changes in the peritoneum, including high glucose, high osmotic pressure, low pH, glucose degradation products, advanced glycation products, etc

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of inhibitor of histone methyltransferase EZH2 to preparing medicine for controlling peritoneum fibrosis after peritoneal dialysis
  • Application of inhibitor of histone methyltransferase EZH2 to preparing medicine for controlling peritoneum fibrosis after peritoneal dialysis
  • Application of inhibitor of histone methyltransferase EZH2 to preparing medicine for controlling peritoneum fibrosis after peritoneal dialysis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Embodiment 1 Materials and methods

[0022] 1) Reagent consumables

[0023] p-STAT3, STAT3, p-Smad3, Smad3, p-NF-κBp65, NF-κBp65, p-EGFR, EGFR, EZH2, α-Tubulin, E-cadherin, H3K27me3, Notch1, Jagged-1, p-Src, Src, MMP2, and MMP9 antibodies were all purchased from cellsignaling Technology. Collagen I (A2), TGF-βRI, CD68, CD3, EGFR, VEGF, CD31 and GAPDH antibodies were purchased from Santa Cruz Company. TNF-α, IL-1β, MCP-1, IL-6, VEGF, CA125 and TGF-β1 (ELISA) kits were purchased from Roche Life Science. 3-DZNeP was purchased from Selleckchem. α-SMA antibody and other reagents were purchased from Sigma.

[0024] 2) Mouse peritoneal fibrosis model and experimental grouping

[0025] The mouse peritoneal fibrosis model was established by intraperitoneal injection of 4.25% high glucose peritoneal dialysis fluid. All animal experiments complied with the Chinese regulations on the management and use of laboratory animals.

[0026] ①28-day 4.25% high-glucose peritoneal dia...

Embodiment 2

[0053] Example 2 EZH2 is highly expressed in peritoneal tissue of patients with peritonitis associated with peritoneal dialysis, and is positively correlated with TGF-β1, VEGF and IL-6 in peritoneal dialysis effluent, and negatively correlated with CA125

[0054] In the peritoneal tissue staining of non-peritoneal dialysis patients and peritonitis-related peritonitis patients, it was found that the positive area of ​​Masson staining in peritonitis patients was significantly higher than that of non-peritoneal dialysis patients, and the expression of EZH2 was also significantly increased ( figure 1 A and 1B). The peritoneal dialysis effluents of patients with peritoneal dialysis at 1 month, 24 months, and 48 months were collected for Western blot detection, and it was found that the longer the peritoneal dialysis age, the higher the expression of EZH2 and Collagen I ( figure 1 C and 1D). ELISA detected the contents of various indicators in the peritoneal dialysis effluent of pa...

Embodiment 3

[0055] Example 3 3-DZNeP inhibits the occurrence of peritoneal fibrosis in mice induced by high glucose peritoneal dialysis fluid (PDF)

[0056] In the animal model, the present invention injects 3 ml of 4.25% high-glucose peritoneal dialysis fluid into mice intraperitoneally, and successfully establishes an animal model of peritoneal fibrosis after 28 days. Masson staining shows that the subperitoneal area of ​​the model is obviously thickened. After daily injection of 3-DZNeP in the treatment group, the thickness of the peritoneum and the positive area of ​​Masson staining could be significantly reduced ( figure 2 A-2C), showing that 3-DZNeP plays an important role in mediating peritoneal fibrosis. Western blotting results showed that EZH2 and H3K27me3 were highly expressed in the peritoneal tissue of mice with peritoneal fibrosis, and the expression of both could be downregulated after using 3-DZNeP ( figure 2 D and 2F). 3-DZNeP can also down-regulate the high expressio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides application of an inhibitor of histone methyltransferase EZH2 to preparing medicine for controlling peritoneum fibrosis after peritoneal dialysis. The inhibitor of the histone methyltransferase EZH2 is 3-DZNeP. The 3-DZNeP is used for inhibiting the histone methyltransferase EZH2, the peritoneum pathology changes caused by exciting of a high-sugar peritoneal dialysis solution can be reduced, and the peritoneum function is improved. An inhibition mechanism inhibits a fibrosis signal channel, inhibits an inflammation signal channel, inhibits releasing of inflammation factors, and reduces angiogenesis. Therefore, the EZH2 can become an important target spot for controlling peritoneum fibrosis, and the inhibitor related to the EZH2 is expected to be clinical medicine forcontrolling occurrence of peritoneum fibrosis after peritoneal dialysis.

Description

technical field [0001] The invention belongs to the field of pharmacy, and relates to histone methyltransferase EZH2, specifically the use of an inhibitor of histone methyltransferase EZH2 in preparing medicines for preventing and treating peritoneal fibrosis after peritoneal dialysis. Background technique [0002] End-stage renal disease (ESRD) is the final stage of irreversible decline in renal function caused by various kidney diseases. Patients can only rely on renal replacement therapy to maintain normal life needs, and it belongs to the category of chronic diseases. In recent years, the incidence of ESRD in the world has increased year by year, and the prognosis is poor, the life expectancy is long, and the cost is high. It has become a global public health problem that seriously endangers human health and increases economic burden. Currently, renal replacement therapy for ESRD mainly includes renal transplantation, hemodialysis and peritoneal dialysis. Peritoneal dia...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/437A61P13/12A61P43/00
Inventor 刘娜施映枫庄守纲
Owner SHANGHAI EAST HOSPITAL EAST HOSPITAL TONGJI UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap